These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36514450)

  • 21. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
    Yan H; Huang C; Shen X; Li J; Zhou S; Li W
    Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Fan S; Shi X; Yao J; Zhong M; Feng P
    Rev Esp Enferm Dig; 2020 Aug; 112(8):627-635. PubMed ID: 32496108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Wang ST; Zheng J; Peng HW; Cai XL; Pan XT; Li HQ; Hong QZ; Peng XE
    BMC Gastroenterol; 2020 Mar; 20(1):66. PubMed ID: 32164541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
    Houttu V; Bouts J; Vali Y; Daams J; Grefhorst A; Nieuwdorp M; Holleboom AG
    Front Endocrinol (Lausanne); 2022; 13():1032164. PubMed ID: 36407307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Xia N
    Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
    Scheen AJ
    Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Haruki U; Yoshikata K; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Hepatol Commun; 2022 Nov; 6(11):3073-3082. PubMed ID: 36039537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials.
    Simental-Mendía M; Sánchez-García A; Rodríguez-Ramírez M; Simental-Mendía LE
    Pharmacol Res; 2021 Jan; 163():105319. PubMed ID: 33246172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel glucose-lowering drugs for non-alcoholic fatty liver disease.
    Fu ZD; Cai XL; Yang WJ; Zhao MM; Li R; Li YF
    World J Diabetes; 2021 Jan; 12(1):84-97. PubMed ID: 33520110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
    Nishimiya N; Tajima K; Imajo K; Kameda A; Yoshida E; Togashi Y; Aoki K; Inoue T; Nakajima A; Utsunomiya D; Terauchi Y
    Intern Med; 2021 Nov; 60(21):3391-3399. PubMed ID: 33994437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes.
    Sinha B; Datta D; Ghosal S
    JGH Open; 2021 Feb; 5(2):219-227. PubMed ID: 33553659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.